MENU

Fox Chase Cancer Center News

Angela R. Bradbury, MD
June 2, 2012

More Cutting-Edge Cancer Research Supported by Industry

CHICAGO, IL (June 2, 2012)––Nearly half of the research presented at ASCO’s annual meeting last year came from researchers with ties to companies, and the amount appears to be increasing every year, according to new findings from Fox Chase Cancer Center. The new findings will be presented this year at the 2012 American Society of Clinical Oncology Annual Meeting on Monday, June 4.

May 10, 2012

Thirty One Fox Chase Cancer Center Physicians Listed Among Region's Best in Philadelphia Magazine’s 2012 “Top Doctors” Issue

PHILADELPHIA (May 10, 2012)—Fox Chase Cancer Center physicians have, once again, made a strong showing in Philadelphia magazine’s annual "Top Doctors" issue — now available on newsstands — with 31 clinicians listed among the region’s best in their specialties by a national survey of professional peers.  The list of “Top Doctors” serves as an important standard for anyone seeking expert medical care in the Philadelphia area.

April 4, 2012

Researchers Uncover a Viable Way for Colorectal Cancer Patients to Overcome Drug Resistance

CHICAGO, IL (April 4, 2012)—When combined with other treatments, the drug cetuximab—which works by slowing or stopping the growth of cancer cells—has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers.  Unfortunately, about 40 percent of colorectal cancer patients—specifically those who carry a mutated form of a gene called KRAS—do not respond to the drug.  Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a

April 4, 2012

Researchers Develop a New Cell and Animal Model of Inflammatory Breast Cancer

CHICAGO, IL (April 4, 2012)—Inflammatory breast cancer (IBC) is a very aggressive, often misunderstood type of cancer that is diagnosed more frequently in younger women compared with other types of breast cancer. The five-year survival rate is between 25 and 50 percent—significantly lower than the survival rate for other types of breast cancer. The reason for the poor prognosis is that IBC usually grows rapidly and often spreads quickly to other parts of the body, including the brain, bone and lymph nodes.

April 3, 2012

New Compound Targets Key Mechanism Behind Lymphoma

CHICAGO, IL (April 3, 2012) – Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma.  The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3.

April 3, 2012

Scientists at Fox Chase Discover Link between Estrogen and Tobacco Smoke

CHICAGO, IL (April 3, 2012) – The hormone estrogen may help promote lung cancer— including compounding the effects of tobacco smoke on the disease—pointing towards potential new therapies that target the hormone metabolism, according to new research presented at the AACR Annual Meeting 2012 on Tuesday, April 3 by scientists at Fox Chase Cancer Center in Philadelphia.

"This research provides the link between estrogen and tobacco smoke," says study author Jing Peng, PhD, postdoctoral associate in the lab of Margie L. Clapper, PhD, also a co-author on the paper.

Sue Coady, RN
April 2, 2012

Fox Chase Cancer Center Nurse Acknowledged with DAISY Award

PHILADELPHIA (April 2, 2012) — Registered nurse Sue Coady is the first Fox Chae nurse to receive the DAISY Award for Extraordinary Nurses. The award celebrates the clinical skill and compassionate care given by nurses in all types of settings.

April 2, 2012

Researchers Uncover New Clues to the Development of Blood and Other Cancers

CHICAGO, IL (April 2, 2012) – Latest findings from Fox Chase Cancer Center reveal that targeting inflammatory pathways may lead to new therapies.

Pages

Connect with Fox Chase